These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 22949223

  • 21. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT.
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [Abstract] [Full Text] [Related]

  • 22. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 23. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C.
    Vaccine; 2012 Feb 01; 30(6):1108-14. PubMed ID: 22178515
    [Abstract] [Full Text] [Related]

  • 24. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.
    Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, Duarte A, Miraglia JL, Timenetsky Mdo C, Viana VS, França IL, Bonfa E, Pereira RM.
    J Rheumatol; 2012 Jan 01; 39(1):167-73. PubMed ID: 22089462
    [Abstract] [Full Text] [Related]

  • 25. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.
    Vaccine; 2012 Nov 06; 30(48):6864-70. PubMed ID: 22989690
    [Abstract] [Full Text] [Related]

  • 26. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.
    Vaccine; 2012 Jul 13; 30(33):5009-18. PubMed ID: 22658967
    [Abstract] [Full Text] [Related]

  • 27. Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis.
    Jain VK, Bhashini N, Balajee LK, Sistla S, Parija SC, Negi VS.
    Indian J Med Res; 2017 Apr 13; 145(4):464-470. PubMed ID: 28862177
    [Abstract] [Full Text] [Related]

  • 28. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB.
    Ann Rheum Dis; 2017 Sep 13; 76(9):1559-1565. PubMed ID: 28468794
    [Abstract] [Full Text] [Related]

  • 29. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O.
    Ann Rheum Dis; 2006 Feb 13; 65(2):191-4. PubMed ID: 16014674
    [Abstract] [Full Text] [Related]

  • 30. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
    Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.
    Vaccine; 2011 Feb 17; 29(9):1777-82. PubMed ID: 21216315
    [Abstract] [Full Text] [Related]

  • 31. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX, Sun N, Ma GY, Wang MM, Sa D, Shi C, Wu JL, Lin X, Xiao Y, Qian YH, Jiang Y, Xie J, Ji YY, Guan HX.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct 17; 25(5):351-4. PubMed ID: 22338222
    [Abstract] [Full Text] [Related]

  • 32. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies.
    Mariotti J, Spina F, Carniti C, Anselmi G, Lucini D, Vendramin A, Pregliasco F, Corradini P.
    Eur J Haematol; 2012 Aug 17; 89(2):111-9. PubMed ID: 22540245
    [Abstract] [Full Text] [Related]

  • 33. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB.
    Ann Rheum Dis; 2018 Jun 17; 77(6):898-904. PubMed ID: 29572291
    [Abstract] [Full Text] [Related]

  • 34. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK.
    J Rheumatol; 2014 Apr 17; 41(4):648-57. PubMed ID: 24584918
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 36. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL, Kivitz AJ, Birbara C, Luo AY.
    J Rheumatol; 2007 Feb 20; 34(2):272-9. PubMed ID: 17304653
    [Abstract] [Full Text] [Related]

  • 37. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.
    França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E.
    Rheumatology (Oxford); 2012 Nov 20; 51(11):2091-8. PubMed ID: 22908326
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R.
    Jpn J Infect Dis; 2011 Nov 20; 64(3):190-4. PubMed ID: 21617301
    [Abstract] [Full Text] [Related]

  • 39. Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients.
    Cordero E, Aydillo TA, Perez-Ordoñez A, Torre-Cisneros J, Lara R, Segura C, Gentil MA, Gomez-Bravo MA, Lage E, Pachon J, Perez-Romero P.
    Transplantation; 2012 Apr 27; 93(8):847-54. PubMed ID: 22377789
    [Abstract] [Full Text] [Related]

  • 40. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ.
    Pediatr Infect Dis J; 2012 Jul 27; 31(7):e92-8. PubMed ID: 22481427
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.